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Our research has focused on the main design features and release performances of time-dependent 
colon-specific (TDCS) delivery tablets, which relies on the relative constancy that is observed in the 
small intestinal transit time of dosage forms. But inflammatory bowel disease（IBD）can affect the 
transit time, and usually results in watery stool. Compared to the TDCS and wax-matrix TDCS tablet, a 
promising time-dependent colon-specific delivery system was investigated. In our study, a suppository-
base-matrix coated tablet was evaluated. Water soluble suppository-base helps the expansion of tablet, 
facilitates uniform film dissolution and achives high osmotic pressure. Combining the expansion of 
carboxymethyl starch sodium (CMS-Na) and the moisture absorption of NaCl, the coated TDCS tablet 
obtained a burst and targeted drug delivery system. A very good correlation between in vitro drug release 
and in vivo outcome was observed. This TDCS coated tablet provides a promising strategy to control 
drug release to the desired lower gastrointestinal region.
Uniterms: Inflammatory bowel disease. Lonicera japonica Thunb/extract. Suppository/colon-specific 
delivery system. Drugs/colon-specific delivery system. Tablets/colon-specific delivery system.
Nossa pesquisa focou-se nas principais características de planejamento e de desempenho de liberação 
cólon-específica tempo-dependente (TDCS) de comprimidos, que leva em conta a constância relativa 
observada no tempo de trânsito intestinal das formas de dosagem. A doença inflamatória do intestino 
(IBD) pode afetar o tempo de trânsito e, geralmente, resulta em fezes aquosas. Comparando ao TDCS e 
a comprimidos TDCS com matriz-cerosa, investigou-se sistema promissor de liberação cólon-específica 
tempo-dependente. Em nosso estudo, avaliou-se comprimido revestido com matriz base de supositório. A 
base de supositório solúvel em água auxilia a expansão do comprimido, facilita a dissolução uniforme do 
filme e atinge alta pressão osmótica. Associando a expansão do carboximetil amido sódico (CMS-Na) à 
absorção de umidade do NaCl, o comprimido revestido TDCS originou sistema de liberação direcionado 
e de erupção. Observou-se correlação muito boa entre a liberação in vitro e a in vivo do fármaco. Este 
comprimido revestido TDCS representa estratégia promissora para o controle da liberação do fármaco 
na região gastrintestinal mais baixa.
Unitermos: Doença inflamatória do intestino. Lonicera japonica Thunb./extrato. Supositório/liberação 
cólon-específica. Fármaco/liberação cólon-específica. Comprimidos/revestidos/liberação cólon específica.
INTRODUCTION
To treat localized colonic diseases, especially IBD, 
we always have to deal with the abnormal colon function 
of the frequent, liquid stools. IBD is a term primarily used 
to refer to two diseases of the intestines: Crohn’s disease 
and ulcerative colitis. In Crohn’s disease, the inflammation 
may involve any area throughout the entire digestive 
tract, often affecting the last part of the small intestine. 
In some cases, ulcerative colitis can involve the entire 
large intestine too. The most commonly seen symptom 
of IBD is diarrhea. Inflammation can affect transit time, 
which usually causes food to pass through more quickly 
and allows less time for drug absorption and increases 
elimination of a drug (Gastrointestinal Society Canadian 
Society of intestinal Research, 2012).
There are currently several strategies to achieve 
colonic specificity, such as bacterially triggered colon-
specific delivery system (Zou et al., 2005; Soodabeh, 
Jalal, Abbas, 1999), pressure-controlled colon-specific 
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delivery system (Yang, Chu, Fix, 2002), pH-dependent 
colon-specific delivery system (Krogars et al., 2000), 
time-dependent colon-specific delivery system (Halsas 
et al., 2001; Cheng et al., 2004), and a combination of 
these methods (Gupta, Beckert, Price, 2001). However, 
bacterially triggered approach is criticized for the concern 
of the highly variable composition of the microflora, which 
can be heavily affected by diet modifications, stress, drug 
intake, and IBD. As with pH-dependent methods, even 
accumulated short-chain fatty acids metabolism might 
account for the erratic performances that have been obtained 
from enteric-coated systems (Gazzaniga et al., 2006).
As far as the time-dependent delivery approaches 
are concerned, a dosage form with a quick burst of drug 
release and a 2-3 h lag time in small intestinal tract is relied 
on for the direct release of bioactive compounds at the 
colon or the last part of the small intestine.
Lonicera japonica Thunb is a medicinal plant usually 
used to effectively treat colitis and cancer in clinical practice 
(Zhu, Hu, 2006; Xia, 2005; Zhang Shao, Wang, 2006). The 
purpose of this study was to explore the feasibility of the 
time-dependent colon-specific suppository-base-matrix 
(TDCS-SBM) tablet with the extract of Lonicera japonica 
Thunb. It is well known that PEG can melt and expand at 
37 °C and ethylcellulose is soluble in PEG. Also, being a 
flexible, water-soluble polymer, PEG can be used to create 
very high osmotic pressures (Money, 1989; Xia, 2005). 
These properties make PEG one of the most suitable 
molecules for TDCS tablet, particularly when used for the 
pulse release system. Utilizing the CMS-Na expanding 
property and all the properties of PEG, the TDCS- SBM 
tablet was designed to achieve not only time-dependent 
but also osmotic film-dissolution controlled drug delivery 
system. A more stable release profile could be obtained as 
compared to the conventional TDCS tablet.
The TDCS-SBM coated tablets consisted of a tablet, 
an inner water-insoluble coating layer, and an enteric outer 
layer. Figure 1 showed the schematic diagram of TDCS-
SBM tablet. During its transit through the GIT, the PEG in 
the core of TDCS-SBM tablet melted. The enteric-coating 
layer dissolved in the small intestine, and water was 
imbibed into the core. The aqueous environment caused 
swelling, high osmotic pressure, film dissolution, and then 
the coating layer was ruptured. Melted PEG core enabled 
the drug to be released in a pulsatile manner.
MATERIALS AND METHODS
Materials
The extract of Lonicera japonica Thunb was 
provided by Ningbo Shuanglin Chinese Traditional 
Medicine Pharmaceutical Co., (chorogenic acid 24%, 
batch No 081102 Ningbo, China). Standard chorogenic 
acid was purchased from the National Institute for the 
Control of Pharmaceutical and Biological Products 
(Beijing, China). PEG 400, PEG 600, PEG 1000, and 
PEG 6000 were obtained from Beijing Haidian Huiyou 
Fine Chemical Industry Factory (CP 2010 Beijing, China). 
Carboxymethyl starch sodium (CMS-Na) USP-NF was 
purchased from Shanghai Yung Zip Pharm Trading Co., 
Ltd. (Shanghai, China). Surelease® aqueous ethylcellulose 
dispersions and Opadry OY-P-7171 were supplied by 
Shanghai Colorcon Co., Ltd. (Shanghai, China). Talc and 
sodium chloride were purchased from Tianjin Kemiou 
Pharmaceutical Co. Ltd. (Tianjin, China). Sucrose was 
provided by Tianjin Bodi Chemical Industry Co. Ltd. 
(Tianjin, China). Microcrystalline cellulose was obtained 
from Asahikasei Chemical Industry Co. Ltd. (MCC, Avicel 
PH101,Tokyo, Japan). Acetonitrile was purchased from 
Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). 
All other chemicals and solvents were of analytical grade, 
and deionized double-distilled water was used throughout 
the study.
Apparatus and chromatographic conditions
The Shimadzu HPLC system (Kyoto, Japan) 
consisted of a LC-10AT pump, a SPD-10A UV detector, 
and a sample injector. The data was acquired and 
processed using an Anastar® software (Shimadzu 
Kyoto, Japan). The analytical column used was Hypersil 
ODS-2 (4.6 mm×250 mm, 5 μm ID) from Dalian Elite 
Analytical Instruments Co., Ltd. (Dalian, China). The 
chromatographic analysis was performed at room 
temperature at a flow rate of 0.8 mL·min−1 with injection 
volume of 20 µL. The UV absorbance was monitored 
at 362 nm. The mobile phase consisted of acetonitrile- 
FIGURE 1 - The schematic diagram of time-dependent colon-
specific suppository- base-matrix (TDCS-SBM) tablet.
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double-distilled water-triethyl ammonium-glacial acetic 
acid (13:87:0.01:0.1, v/v).
Preparation of the tablets
The basic tablets consisted of 40% (w/w) dry extract 
of Lonicera japonica Thunb, 20% (w/w) CMS-Na, 20% 
(w/w) PEG, 8% (w/w) sodium chloride, 10% (w/w) MCC 
and 2% (w/w) talc. PEG 6000 and PEG 600 or PEG 400 
were melted for mixture and cooled. Drug and excipients 
(except talc) were sieved (mesh 80) and blended by 
sieving; the mixtures were granulated with 95% alcohol 
(mesh 20) and were dried for 2 h at 30 °C. Core tablets with 
average weight of 310 mg were prepared using a single 
punch tablet machine (Type-TDP, 1st Pharm Machine 
Manu. Co., Shanghai, China). The diameter of core tablets 
was 8.5 mm with round beveled. The hardness of the tablet 
was controlled at 5-7 kg/mm2. The influence of the types of 
binder or moistening and PEG was investigated. Similarly, 
the effect of the amount of CMS-Na, NaCl, and PEG was 
also evaluated with sucrose as diluents to adjust tablets 
weight to 310 mg.
Preparation of the coated tablets
The core tablets were coated in a conventional 
rotating pan. The basic inner- coating formulation was 
15% Surelease® which contained PEG 400 (1.0%, w/w) 
as channeling agent with 7% weight gain (theoretical solid 
content of Surelease consumed). Operating conditions 
were as follows: the rotation speed, 30-45 rpm; coating 
pan angle, 45°; the nozzle port size, 0.8 mm; inlet air 
temperature, 35 °C; tablet bed temperature, 25 °C; sprayed 
flow rate, 0.7 mL/min. The outer-coating material was 
Opadry OY-P-7171 in 90% ethanol. The weight gain 
of outer enteric layer material was 8% w/w. Operating 
conditions were the same as the above except for the spray 
rate at 1.0 mL/min with inlet temperatureat 30 °C and 
outlet temperature at 25 °C.
In vitro dissolution test
All dissolution tests were performed using USP 
type II dissolution apparatus (ZRD6-B dissolution 
tester, Shanghai Huanghai Instrument Factory, Shanghai 
China). Place 750 mL of 0.1 N hydrochloric acid in the 
vessel, and assemble the apparatus. Allow the medium 
to equilibrate to a temperature of 37±0.5 °C. Place 6 
tablets in the apparatus, cover the vessel, and operate 
the apparatus for 2h at the rate of 75 rpm. After 2 h of 
operation in 0.1 N HCl, withdraw an aliquot of the solution 
and immediately add 250 mL of 0.20 M tribasic sodium 
phosphate equilibrated to 37±0.5 °C to the solution in the 
vessel. Adjust, if necessary, with 2 N hydrochloric acid or 
2 N sodium hydroxide to a pH of 6.8±0.05. For the release 
study of the formulation screening, withdraw an aliquot 
of the fluid at the film rupture time, and 30, 60, 90, 120, 
150, 180 min after film rupture. The film rupture time 
was defined as the time at which amount of drug release 
was greater than 10%. For the optimized formulation, 
withdraw a specimen at 3, 4, 4.5, 5, 5.5, 6, 6.5, 7 and 7.5 h. 
After each sampling, lost volume was replaced with equal 
volume of the fresh medium to maintain constant total 
volume. The solutions were immediately filtered through 
a 0.45 μm membrane and determined by HPLC.
Dissolution testing conditions were selected based 
on a screening study using USP apparatus 2. According 
to USP, dissolution medium may be water, or a buffered 
aqueous solution (typically pH 4.0 to 8.0). After 2 hours 
of operation in 0.1 N HCl, release profiles under different 
dissolution media (double distilled water, pH 6.8, pH 7.0, 
pH 7.4, and pH 7.8 phosphate buffer) were evaluated. 
Effect of varying paddle speeds of 50, 75, 100, and 
150 rpm were also investigated with water media.
Statistic analysis
One-way analysis of variance test (ANOVA) 
was performed to check whether there was significant 
difference among the formulations. Release profiles of 
TDCS tablet, TDCS-SBM tablet, and WM-TDCS tablet 
were compared using ‘the fit factors’, which included the 
calculation of similarity factor f2. According to this theory, 
two release profiles were considered to be similar if f2 
value was greater than 50 (between 50 and 100) (Jeffrey, 
Henry, 1996; Xia, Liu., 2000).
Experimental protocol in vivo
Technetium-99 m pertechnetate eluate containing 
approximately 370 MBq of activity was dropped on the 
top of the two sides of the core tablets (a few tablets made 
manually). Then the core tablets were coated as described 
in previous section.
All studies were performed according to the 
Guidelines that were approved by the Ethics Committee 
on Human Subjects of the General Military Hospital. Two 
healthy, male volunteers were selected for the in vivo studies. 
First of all, a 99Tc labeling coated tablet was administered. 
After administration, the volunteers immediately were laid 
on their backs under the monitor of Sophy DSX-NXT Spect 
system (Sophy, Buc, France). The movement of the coated 
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tablet was followed by gamma scintigraphy. The image was 
collected at appropriate intervals for a period of 0.5 min. 
Energy was selected as 140 Kev; window width was 20%; 
collecting matrix was 256×256. Regions of interest were 
drawn around the site of movement and the total activity in 
this area representing the amount of released drug substance 
was characterized (George, 1996).
RESULTS
Validation of assay method
The retention time of chorogenic acid in HPLC 
was about 6.3 min. The linear regression equation of the 
calibration curve was A=18 004 c +55.886, (r＝0.999)
over the concentration range of 0.5~20.0 μg/mL. The limit 
of quantification (LOQ) was 0.25 μg/mL. The criteria of 
precision, accuracy and recovery for analyzing samples 
were fulfilled in the developed analytical method.
Effect of different tablet formulations
Influence of binders or moistening agent
The formulations granulated using 95% ethanol and 
5% PVP in 95% ethanol solution gave a suitable hardness 
of tablets and the appearance of the tablets was uniform. 
However, formulations granulated with 5% ethylcellulose 
in 95% ethanolic solution did not yield the required 
hardness. To keep the formulation simple, 95% ethanol 
was selected as moistening agent.
Effect of amount of CMS-Na and NaCl on drug release
For the effect of CMS-Na and NaCl on drug release, 
same results were obtained as studied by Zou et al. (2009). 
It showed that the combination of CMS-Na and NaCl had 
significant influence on film rupture time for TDCS tablet; 
and the former exhibited higher effect. The influence 
of sodium chloride on drug release could be due to the 
osmotic pressure.
Effect of the types of PEG on drug release
Polymers with appropriate expanding, osmotic 
pressure, and also film- dissolution property can be used 
for colon-specific delivery system. Dissolutions of the 
three types of PEG core coated tablets (with basic inner 
layer) showed that there were no significant differences for 
the release profile. The volume expansion degree of three 
types of PEG was evaluated. 10 g of PEG 1000, PEG 6000: 
PEG 400(1:2.1), or PEG 6000: PEG 600(1:1) was placed 
into a graduated test tube and then was melted. The melting 
(37 °C) and room temperature volumes were determined. 
It showed that the increases in the melting volume of PEG 
1000, PEG 6000-PEG 400 (1:2.1), and PEG 6000-PEG 
600 (1:1) were 17.2 ± 0.5%, 15.7±0.7%, and 16.4±0.4%, 
and exhibited no significant difference. Hence PEG 1000 
was selected as the suppository-base-matrix of the tablet 
for the future study.
Effect of amount of PEG on drug release compared 
with the WM-TDCS tablet
The tablet formulations (Table 1) containing 0%, 
10%，20%，30% PEG 1000 with basic inner- and 
outer-coating layer were investigated. The drug release 
profiles of each formulation were presented in Figure 2. 
It was evident that the mean film rupture of TDCS-SBM 
tablet containing 10%，20% PEG 1000 was similar with 
TDCS. TDCS- SBM tablet containing 30% PEG1000 
showed more rapid film rupture time. Also the drug 
release from TDCS-SBM and WM-TDCS tablet was 
better reproducible than that of TDCS tablet with higher 
variability. Furthermore, TDCS-SBM tablet exhibited a 
burst drug release. It showed that the drug release from 
TDCS-SBM tablet reached about 70% within 0.5 to 
1.0 h.
TABLE I - Formulations of core tablets with wax or different concentrations of PEG1000
Formulation 1 2 3 4 5
Extract of Lonicera japonica Thunb (%) 40 40 40 40 40
PEG1000 (%) - 10 20 30 -
Wax (%) - - - - 20
CMS-Na (%) 20 20 20 20 20
NaCl (%) 8 8 8 8 8
MCC (%) 10 10 10 - 10
Sucrose (%) 20 10 - - -
Talc (%) 2 2 2 2 2
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One-way ANOVA was performed to check whether 
there was significant difference of drug release among 
the same formulations; and the value of p was not 
statistically significant. Comparing the release of each 
other within the same formulation (with 9 release points), 
the ‘similarity factor’ f2 of TDCS tablet was 44.2 ± 7.4 
and others were more than 50 by the fit factors method. 
The results in Table II suggested that the release of tablets 
from TDCS-SBM and WM-TDCS was considered to be 
similar to each other.
Effect of the pore forming agent and the inner-
coating membrane on drug release
With this study, it is concluded that core tablets 
coated with Surelease® containing no pore forming agent 
with weight gain 7% had no drug release within 24 h. 
While the amount of PEG 400 was 2.0%, tablets coated 
with weight gain 12% achieved about 3 h lag time. Finally, 
TABLE II - The f2 of the dissolution profile of tablets between the same formulations with 9 release points
Formulation 
f2 compared with No.1 tablet of each formulation
2 3 4 5 6 Mean SD
TDCS 48.2 35.8 48.9 36.7 51.3 44.2 7.4
WM-TDCS 52.1 67.7 45.9 71.4 66.7 60.8 11.1
TDCS-SBM, 10%PEG 60.5 53.2 61.0 55.5 58.0 57.6 3.3
TDCS-SBM, 20%PEG 54.3 51.7 66.9 56.5 63.1 58.5 6.3
TDCS-SBM, 30%PEG 64.5 73.4 57.8 58.0 69.7 64.7 7.0
Note: TDCS means time-dependent colon-specific tablet; SBM means suppository- base-matrix; WM means wax matrix
FIGURE 2 - Drug release profile from TDCS, WM-TDCS, and 
TDCS-SBM coated tablets (n=6).
1.0% PEG 400 was selected. The in vitro release behaviors 
of the inner-coated tablets for basic core tablet with 
different inner-coating levels (3%, 5%, 7%, 9%, 10% and 
11% w/w) of Surelease® were studied. As shown in Table 
III, the tablets with a weight gain of 7% of Surelease® were 
selected as the optimized formulation.
Effect of different dissolution conditions
After 2 hours of operation in 0.1 N HCl, release 
profiles under different dissolution media (distilled 
water, pH 6.8, pH 7.0, pH 7.4, and pH 7.8 phosphate 
buffer) were evaluated. It was demonstrated that 
the drug release lag time and the drug release were 
independent of the dissolution media since the inner 
coating material, Surelease®, was pH-independent. The 
release characteristics of the formulation were to be 
evaluated over the physiologic pH range, pH 7.4.
The release profile showed no difference in the 
liberation of the active substance at paddle speed of 50, 75, 
100, and 150 rpm. At the latter stage of the drug release, 
the greater the paddle speed was, the faster the release rate 
with no significant difference. For these studies, the paddle 
speed was selected at 75 rpm.
γ-Scintigraphy photos in vivo
Consequently, gamma scintigraphy was employed to 
study the colon release of the drug in our two volunteers. 
Figure 3 showed the movement traces of the tablet after 
administration of the extract of Lonicera japonica Thunb 
coated tablets. As shown in the γ-scintigraphy photos, it 
was suggested that the break-up of the film coated tablets 
occurred in the human colon. The photographs revealed 
that radioactivity from the coated tablets remained in 
the stomach at 2 h after administration. At the 3rd hour 
it reached small intestinal. At the 4th hour it was still in 
small intestine with limited drug release. When it reached 
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ascending colon at the 5th hour, drug was released 
completely for both of the two volunteers.
DISCUSSIONS
It is well documented that gastric emptying of a 
preparation varies. In contrast, the transit time in small 
intestine for the preparation is surprisingly constant at 
3±1 h and appears to be independent of the types of the 
preparations and whether subjects are fed or not (Halsas 
et al., 2001; Muraoka, Shimokawa, 1998). Based on 
these understandings, we designed the enteric time-
dependent colon-specific drug delivery system to achieve 
a considerable drug release after the preparation’s arrival 
into the colon.
A new time-dependent colon-specific suppository-
base-matrix delivery system of extract of Lonicera 
japonica Thunb was developed based on the volume 
expanding of core tablet, high osmotic pressure, film 
dissolution, and time-dependent properties. The in vitro 
and in vivo studies indicated that it is feasible to use 
TDCS-SBM tablet to achieve stable drug release in colon 
independent of pH values and paddle agitation speed. 
Comparing TDCS-SBM with TDCS and other time-
controlled release system (Halsas et al., 2001), the lag 
time and drug release were more stable. The drug release 
of TDCS-SBM tablet showed pulsatile manner, which is 
different from the WM-TDCS tablet. It is beneficial for 
the treatment of IBD.
The drug release profiles of TDCS-SBM tablet with 
inner coated layer were not affected by the pH values of the 
media. This was reasonably expected, since the channeling 
agent PEG 400 was pH-insensitive and the formation 
of the micro-channels was not affected by pH value. 
The hydrophobic Surelease® membrane was relatively 
impermeable to water molecules; hence it controlled the 
rate of the water molecules diffusion and water uptake. 
The weight gain of the coating layer certainly determined 
the rate of water uptake, by controlling the formation rate 
of the aqueous channels. The ability of the disintegrating 
agent to expand was also one of the key factors for time-
dependent controlled release (Fan et al., 2001).
CONCLUSIONS
From the results of in vitro and in vivo, this study 
showed that TDCS-SBM tablet achieved a drug release in 
pulsatile manner with a 2-3 h lag time in small intestine. 
PEG has film-dissolution property and is water soluble, 
the drug release of TDCS-SBM hence showed a pulsatile 
manner different from the WM-TDCS tablet. It is 
beneficial for the treatment of IBD. Since PEG can melt 
and expand at 37 °C, dissolve ethyl cellulose and create 
osmotic pressures, TDCS-SBM tablet can obtain a quick 
burst of drug release after 2-3 h lag time in small intestine. 
This study provides a promising strategy for colon-specific 
drug delivery using “a time delay” as the release trigger.
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TABLE III - Influence of weight gain (observed value) of inner layer with PEG 0.1% on film rupture time in pH 6.8 phosphate 
buffer (n=6)
Weight gain (%) 3 5 7 9 10, 11
Film rupture time (h) 0.4±0.5 1.7±0.8 3.1±0.6 7.8±1.1 >12
FIGURE 3 - Results of γ-scintigraphy technique for release 
of technetium-99 coated time-dependent colon-specific 
suppository-base-matrix (TDCS-SBM) tablet.
A suppository-base-matrix tablet for time-dependent colon-specific delivery system 541
REFERENCES
CHENG, G.; AN, F.; ZOU, M.J.; SUN, J.; HAO, X.H.; HE, 
Y.X. Studies on the diclofenac sodium time-dependent and 
5-aminosalicylic acid pH dependent oral colon- specific 
drug delivery systems. World J. Gastroenterol., v.10, n.12, 
p.1769-1774, 2004.
FAN, T.Y.; WEI, S.L.; YAN, W.W.; CHEN, D.B.; LI, J. An 
investigation of pulsatile release tablets with ethylcellulose 
and Eudragit L as film coating materials and cross- linked 
polyvinylpyrrolidone in the core tablets. J. Control Release, 
v.77, 3p.245-251, 2001.
GASTROINTESTINAL SOCIETY CANADIAN SOCIETY 
OF INTESTINAL RESEARCH. What is IBD?: symptoms/
complications, diagnosis, management. Available at: http://
www. badgut.org/information-centre/inflammatory-bowel-
disease. html. Accessed on: 20 Dec. 2012.
GAZZANIGA, A.; MARONI, A.; FOPPOLI, A.; PALUGAN, 
L. Oral colon delivery: rationale and time-based drug design 
strategy. Discov. Med., v.36, n.6, p.223-228, 2006.
GEORGE, A.A. Evaluation of the gastric retention properties 
of a cross-linked polymer coated tablet versus those of a 
nondisintegrating tablet. Int. J. Pharm., v.75, n.2-3, p.241-
247, 1996.
GUPTA, V.K.; BECKERT, T.E.; PRICE, J.C. A novel pH- and 
time-based multi-unit potential colonic drug delivery 
system. I. Development. Int. J. Pharm., v.213, n.1-2, p.83-
91, 2001.
HALSAS, M.; PENTTINEN, T.; VESKI, P.; JURJENSON, H.; 
MARVOLA, M. Time-controlled release pseudoephedrine 
tablets: bioavailability and in vitro/in vivo correlations. 
Pharmazie, v.56, n.9, p.718-723, 2001.
JEFFREY, W.M.; HENRY, H.F. Mathematical comparison of 
dissolution profiles. J. Pharm. Technol., v.20, p.64-74, 1996.
KROGARS, K.;  HEINAMAKI, J. ;  VESALAHTI, J. ; 
MARVOLA, M.; ANTIKAINEN, O.; YLIRUUSI, J. 
Extrusion- spheronization of pH-sensitive polymeric matrix 
pellet for possible colonic drug delivery. Int. J. Pharm., 
v.199, n.2, p.187-194, 2000.
MONEY, N.P. Osmotic pressure of aqueous polyethylene 
glycols. relationship between molecular weight and vapor 
pressure deficit. Plant Physiol., v.91, n.2, p.766-769, 1989.
MURAOKA, M.; HU, Z.; SHIMOKAWA, T. Evaluation 
of intestinal pressure-controlled colon delivery capsule 
containing caffeine as a model drug in human volunteers. 
J. Control. Release, v.52, n.1-2, p.119-129, 1998.
SOODABEH, D.; JALAL, H.; ABBAS, K. Release of 5-ASA 
from acrylic type polymeric prodrugs designed for colon-
specific drug delivery. J. Control. Release, v.58, n.3, p.279-
287, 1999.
XIA, R. Study on determination method and pharmacokinetics 
of chlorogenic acid in animals after mainline. Sichuan, 2005. 
p.18-20.(Thesis of Master degree. Sichuan University.).
XIA, J.H.; LIU, C.X.; The statistical evaluation and analysis of 
in vitro dissolution of solid preparation. J. Chin. Pharm., 
v.35, p.1-2, p.345-349, 2000.
YANG, L.; CHU, J.S.; FIX, J.A. Colon-specific drug delivery: 
new approaches and in vitro/in vivo evaluation. Int. J. 
Pharm., v.235, n.1-2, p.1-15, 2002.
ZHANG, X.T.; SHAO, W.H.; WANG, W. The preparation and 
application of extract of Flos loniceare. CN Pat. 1730015A, 
2006.
ZHU, S.C.;  HU, H.Q. The chemical constituent and 
pharmaceutical action of Lonicera japonica Thunb. 
Heilongjiang Med. J., n.4, p.299, 2006.
ZOU, M.J.; OKAMOTO, H.; CHENG, G.; HAO, X.; SUN, 
J.; CUI, F.; DANJO, K. Synthesis and properties of 
polysaccharide prodrugs of 5-aminosalicylic acid as 
potential colon-specific delivery systems. Eur. J. Pharm. 
Biopharm., v.59, n.1, p.155-160, 2005.
ZOU, M.J.; WANG, Y.; XU, C.H.; CHENG, G.; REN, J.G.; WU, 
G.L. Wax-matrix tablet for time-dependent colon-specific 
delivery system of Sophora flavescens Aiton: preparation 
and in vivo evaluation. Drug Dev. Ind. Pharm., v.35, n.2, 
p.224-233, 2009.
Received for publication on 17th June 2013
Accepted for publication on 16th December 2013

